No­var­tis’ $650M cash bet on a near-term FDA OK for BeiGene’s Chi­na PD-1? It just got de­layed in­def­i­nite­ly

A not-so-fun­ny thing hap­pened to No­var­tis’ high-pro­file bid to take a PD-1 check­point out of Chi­na and get it ap­proved in the US this year.

Af­ter pay­ing BeiGene $650 mil­lion for US-plus ex-Chi­na com­mer­cial­iza­tion rights for the drug — the lat­est in a long string of con­tenders to fol­low Keytru­da and Op­di­vo — the FDA is de­fer­ring ac­tion on their ap­pli­ca­tion.

And there’s no new time­line on when the agency will make a de­ci­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER